tiprankstipranks
Trending News
More News >

BofA moves to No Rating on SpringWorks Therapeutics

BofA is moving to No Rating on SpringWorks Therapeutics (SWTX) given that shares are trading near the Merck KGaA (MKGAY) potential offer price of $47 per share and “no longer trading on fundamentals.” A $47 per share price, while below expectations, would be a validation of the market opportunity for Gomekli and Ogsiveo, the analyst stated.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue